Leukemia: all 5,475 studies

Page 34 of 55. Open to participants first (629), then studies with results posted, then the rest; newest registration first within each.

• Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AMLWithdrawnNCT02238522Phase 1
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02236013Phase 1
• Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
• Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AMLTerminatedNCT02229266Phase 2
• Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older AdultsCompletedNCT02228772Phase 1
• Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
• Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive ChemotherapyTerminatedNCT02226497Not applicable
• An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Effect of 2nd Gen TKI in CMLCompletedNCT02222272
• Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
• Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT02215629Phase 1
• Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic SyndromeCompletedNCT02212561Phase 1
• Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
• A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML PatientsTerminatedNCT02204722Phase 4
• Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDSWithdrawnNCT02204020Phase 2
• Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsCompletedNCT02203825Phase 1
• Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)TerminatedNCT02203773Phase 1
• A Study for Improving the Outcome of Childhood Acute Promyeloid LeukemiaCompletedNCT02200978Phase 4
• Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02200848Phase 1
• A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
• Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT02198482Phase 2
• A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseCompletedNCT02197676Phase 2
• Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of AsparaginaseNo longer availableNCT02197650
• Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
• Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer CenterWithdrawnNCT02193100
• Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDSCompletedNCT02190695Phase 2
• Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood TransplantationCompletedNCT02188290
• Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic LeukemiaStatus unknownNCT02186860Phase 1
• Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT02185781Phase 1
• DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLCompletedNCT02182596Phase 1/2
• Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02181699Phase 1
• Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02181660Phase 1
• Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
• "InDACtion" vs "3+7" Induction in AMLStatus unknownNCT02172872Phase 3
• Allogeneic SCT for CML, TKI Failure After TKI FailureStatus unknownNCT02172365
• Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid LeukemiaStatus unknownNCT02171117Phase 3
• CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
• CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
• Study of Efficacy and Safety of CTL019 in Adult ALL PatientsWithdrawnNCT02167360Phase 2
• LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
• Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus RituximabCompletedNCT02157181Phase 2
• Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite ProjectStatus unknownNCT02156726
• An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)WithdrawnNCT02150928Phase 2
• Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoLTerminatedNCT02147873Phase 2
• Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic LeukemiaCompletedNCT02144623Early Phase 1
• A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL GeneCompletedNCT02141828Phase 1
• Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
• Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)Status unknownNCT02140606Phase 1
• Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AMLCompletedNCT02140242Phase 3
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL PatientsTerminatedNCT02137889Phase 1
• Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic LeukemiaApproved for marketingNCT02136511
• Yoga Fatigue StudyTerminatedNCT02134782Not applicable
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
• Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
• Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their ChildrenCompletedNCT02129049Not applicable
• Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDSStatus unknownNCT02124174Phase 2
• Natural Killer Cells in Acute Leukaemia and Myelodysplastic SyndromeStatus unknownNCT02123836Phase 1
• Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT02122081Phase 1
• Exergaming Intervention in ALL PatientsCompletedNCT02118324Not applicable
• Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)SuspendedNCT02117336Phase 1
• SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous LeukemiaWithdrawnNCT02115672Phase 1/2
• Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
• Ribomustin in the First Line Therapy of Chronic Lymphocytic LeukemiaCompletedNCT02110394
• Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLTerminatedNCT02109627Phase 1
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CTCompletedNCT02103530Not applicable
• Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
• TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02100852Phase 1
• A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.CompletedNCT02098967Phase 1
• Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02096289Phase 1
• Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02093403Phase 1
• Red Cell Transfusion Goals in Patients With Acute LeukemiasCompletedNCT02086773Phase 1
• Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)CompletedNCT02085798
• Study of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsCompletedNCT02084563Phase 2
• Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
• A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedNCT02081378Phase 1
• An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic LeukemiaCompletedNCT02080884
• A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)CompletedNCT02078609Phase 1
• "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute LeukemiaCompletedNCT02074657Phase 2
• Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AMLCompletedNCT02073838Phase 2
• Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid LeukemiaStatus unknownNCT02072811Phase 3
• Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic LeukemiaStatus unknownNCT02072785Phase 3
• Study of the Glutaminase Inhibitor CB-839 in LeukemiaCompletedNCT02071927Phase 1
• Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:Status unknownNCT02070523Phase 3
• Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02070458Phase 1
• MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted MethotrexateCompletedNCT02067143Phase 2
• CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/2
• Haplo-SCT vs ASCT With or Without Decitabine in AML CR1Status unknownNCT02059720Phase 3
• Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02057770Phase 1
• Occupational Status and Hematological DiseaseCompletedNCT02057185
• MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02049801Phase 1
• Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.Status unknownNCT02047578Phase 2
• Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous LeukemiaTerminatedNCT02047149Phase 1
• Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT02046928Phase 2
• Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic LymphomaTerminatedNCT02043587Phase 2
• Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia PatientsCompletedNCT02042690Phase 3
• A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AMLCompletedNCT02040506Phase 1

← Leukemia overview